
BioRestorative Therapies, Inc. Common Stock (NV)
BRTX
BRTX: BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
moreShow BRTX Financials
Recent trades of BRTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BRTX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Human brown adipose derived stem cells and uses Jun. 06, 2023
-
Patent Title: Brown fat cell compositions and methods Jul. 20, 2021
-
Patent Title: Human brown adipose derived stem cells and uses Mar. 09, 2021
-
Patent Title: Human brown adipose derived stem cells and uses Jan. 01, 2019
-
Patent Title: Brown fat cell compositions and methods Sep. 15, 2015
Federal grants, loans, and purchases
Followers on BRTX's company Twitter account
Number of mentions of BRTX in WallStreetBets Daily Discussion
Recent insights relating to BRTX
Recent picks made for BRTX stock on CNBC
ETFs with the largest estimated holdings in BRTX
Flights by private jets registered to BRTX